Aethlon Medical has entered into an agreement with GVK Biosciences to expand the opportunity to commercialise Hemopurifier treatment technology at three to five new clinical centers in India.
Hemopurifier is a medical device that selectively targets the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. It safely reduces viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drug.
Aethlon and GVK Bio said that the therapeutic focus at each center will be the implementation of the Hemopurifier as an adjunct therapy to accelerate the benefit of HCV standard of care (SOC) drug regimens.
Accordingly, therapeutic filtration at the outset of SOC improves early virus reduction kinetics to levels associated with patients most likely to achieve a sustained viral response, which is the goal of HCV therapy.
Aethlon further disclosed that the Ethics Review Board (ERB) at Medanta, The Medicity Institute (Medicity) had met to discuss the potential approval for Aethlon to initiate HCV treatment programs at the Medicity.
Aethlon has been advised that a formal response should be expected from the Medicity ERB soon.